Table 1.

Adverse bleeding and thrombotic events of drotrecogin alfa (activated) and placebo in the PROWESS study^*

	No. of patients (%)
Event	Placebo (n = 840)	Drotrecogin alfa (activated) (n = 850)	P value
Gastrointestinal bleeding	9 (1.1)	9 (1.1)
Intra-abdominal bleeding	4 (0.5)	3 (0.4)
Intrathoracic bleeding	1 (0.1)	6 (0.7)
Retroperitoneal bleeding	0	4 (0.5)
Intracranial bleeding	1 (0.1)	2 (0.2)
Skin or soft tissue bleeding	0	2 (0.2)
Genitourinary bleeding	0	2 (0.2)
Unidentified source bleeding	2 (0.2)	2 (0.2)
Total serious bleeding events	17 (2.0)	30 (3.5)	0.06
Thrombotic events	25 (3.0)	17 (2.0)	0.2

*From reference 9.

PROWESS indicates the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.